Cheng Du Sheng Nuo Biotec Co., Ltd. (688117.SH) Latest Company News

Oct 16, 2026, 11:28 UTC
China’s National Medical Products Administration issued a drug registration certificate for terlipressin injection to Chengdu Shengnuo Biopharmaceutical Co., Ltd.
Source:
- finance.sina.cn
Oct 13, 2026, 10:56 UTC
Sichuan Huilong Pharmaceutical Technology Co., Ltd. received an EU export active pharmaceutical ingredient certificate for tirzepatide, valid through October 11, 2029.
Source:
- finance.sina.cn
Oct 9, 2026, 14:41 UTC
The Nanjing Yuhuatai District People's Procuratorate indicted Sichuan Shengnuo Pharmaceutical Co., Ltd.'s wholly owned subsidiary Shengnuo Pharmaceutical and its actual controller and chairman Wen Yongjun for suspected bid-rigging in the seventh national drug procurement program.
Source:
- finance.sina.cn
Oct 8, 2026, 08:13 UTC
Shengnuo Biotechnology Deputy General Manager and Board Secretary Rao Jin had not begun his planned purchase of company shares as of October 8, 2026, and said he would continue to pursue the plan during its implementation period.
Source:
- finance.sina.cn
Sep 3, 2026, 11:10 UTC
Shengnuo Biopharmaceutical's wholly-owned subsidiary Chengdu Shengnuo Biopharmaceutical received a drug registration certificate from China's National Medical Products Administration for linaclotide capsules (290μg), approving the product for market.
Source:
- finance.sina.cn
Aug 28, 2026, 10:34 UTC
Sino Bio's wholly-owned subsidiary Chengdu Sino Bio Pharmaceutical received approval from China's National Medical Products Administration for the registration of its active pharmaceutical ingredient terlipressin acetate, packaged at 10g per bottle.
Source:
- finance.sina.cn
Aug 19, 2026, 10:18 UTC
Shengnuo Biopharmaceutical announced its first-half 2026 results: net profit attributable to shareholders was 135 million yuan, up 51.98% year-on-year.
Source:
- finance.sina.cn

688117.SH

China’s National Medical Products Administration issued a drug registration certificate for terlipressin injection to Chengdu Shengnuo Biopharmaceutical Co., Ltd.

Sichuan Huilong Pharmaceutical Technology Co., Ltd. received an EU export active pharmaceutical ingredient certificate for tirzepatide, valid through October 11, 2029.

The Nanjing Yuhuatai District People's Procuratorate indicted Sichuan Shengnuo Pharmaceutical Co., Ltd.'s wholly owned subsidiary Shengnuo Pharmaceutical and its actual controller and chairman Wen Yongjun for suspected bid-rigging in the seventh national drug procurement program.

Shengnuo Biotechnology Deputy General Manager and Board Secretary Rao Jin had not begun his planned purchase of company shares as of October 8, 2026, and said he would continue to pursue the plan during its implementation period.

Shengnuo Biopharmaceutical's wholly-owned subsidiary Chengdu Shengnuo Biopharmaceutical received a drug registration certificate from China's National Medical Products Administration for linaclotide capsules (290μg), approving the product for market.

Sino Bio's wholly-owned subsidiary Chengdu Sino Bio Pharmaceutical received approval from China's National Medical Products Administration for the registration of its active pharmaceutical ingredient terlipressin acetate, packaged at 10g per bottle.

Shengnuo Biopharmaceutical announced its first-half 2026 results: net profit attributable to shareholders was 135 million yuan, up 51.98% year-on-year.